Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

PIK3CA-Related Overgrowth Spectrum: molecular mechanisms and preclinical modelling of PIK3CA VARIANTs

Descrizione del progetto

Approfondimento meccanicistico sullo spettro di crescita eccessiva correlato a PIK3CA

Lo spettro di crescita eccessiva correlato a PIK3CA (PROS, PIK3CA-related overgrowth spectrum) comprende disturbi associati alla crescita eccessiva di alcune parti del corpo, nonché lesioni vascolari. Il PROS è causato da mutazioni attivanti del gene PIK3CA nelle cellule somatiche, e i pazienti sono sottoposti a interventi chirurgici impegnativi, con un alto rischio di recidiva della malattia. Il progetto PROS-VARIANT, finanziato dall’UE, mira a comprendere i meccanismi molecolari alla base dello sviluppo del PROS. Più specificamente, i ricercatori determineranno i tempi, il tipo di cellula e la variante PIK3CA che contribuiscono alla gravità del PROS. Le risultanze molecolari saranno convalidate in modelli preclinici e alimenteranno la ricerca futura verso nuovi trattamenti.

Obiettivo

PIK3CA-related overgrowth spectrum (PROS) is a group of rare congenital disorders that manifest as complex syndromes with overgrowth of several tissues (vasculature, adipose and muscle tissues, bones, brain and skin among others) or as localized lesions such as vascular malformations. PROS is caused by somatic activating mutations in the PIK3CA gene that arise postzigotically during embryonic development. Patients suffer dramatic functional and life-threatening complications and typically require extensive mutilating surgery, pulsed laser, and/or sclerotherapy. However, these treatment strategies are insufficient, and patients commonly experience a high risk of recurrence and progression. This is in part a reflection of poor understanding of the underlying cellular and molecular mechanism of their onset and progression. In this proposal, I aim to gain physiological and molecular insight into PROS and address fundamental biological questions concerning when (timing), where (cell linage), who (PIK3CA variant) and how (triggered mechanism) activating PIK3CA variants contribute to the development and severity of PROS. I will address the following key objectives: 1) identify the specific molecular and cellular alterations triggered by strong (H1047R) and weak (E726K) activating PIK3CA variants and 2) characterize their spatiotemporal pathogenesis in PROS using novel mice models. To this end, a combination of in vitro and in vivo approaches, using novel genetically modified mice will be implemented in order to provide new mechanistic insight into the underlying disease pathology and give rise to new preclinical models to test therapeutic treatments. Achieving these goals will strongly contribute to my training as international expert in PI3K signaling, cell biology and congenital diseases, my experimental skillset, and my development towards a well-embedded and independent researcher within European academia.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2020

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Contributo netto dell'UE
€ 160 932,48
Indirizzo
CARRETERA DE CAN RUTI CAMI DE LES ESCOLES S/N
08916 Badalona
Spagna
Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 160 932,48